Lena Harries1,2, Jill Gwiasda3, Zhi Qu4,3, Harald Schrem3,5, Christian Krauth4,3, Volker Eric Amelung4,3. 1. Department of Health Economics and Health Policy, Institute of Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. harries.lena@mh-hannover.de. 2. Core Facility Quality Management Transplantation, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. harries.lena@mh-hannover.de. 3. Core Facility Quality Management Transplantation, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. 4. Department of Health Economics and Health Policy, Institute of Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. 5. Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany.
Abstract
INTRODUCTION: Identification of cost-driving factors in patients undergoing liver transplantation is essential to target reallocation of resources and potential savings. AIM: The aim of this study is to identify main cost-driving factors in liver transplantation from the perspective of the Statutory Health Insurance. METHODS: Variables were analyzed with multivariable logistic regression to determine their influence on high cost cases (fourth quartile) in the outpatient, inpatient and rehabilitative healthcare sectors as well as for medications. RESULTS: Significant cost-driving factors for the inpatient sector of care were a high labMELD-score (OR 1.042), subsequent re-transplantations (OR 7.159) and patient mortality (OR 3.555). Expenditures for rehabilitative care were significantly higher in patients with a lower adjusted Charlson comorbidity index (OR 0.601). The indication of viral cirrhosis and hepatocellular carcinoma resulted in significantly higher costs for medications (OR 21.618 and 7.429). For all sectors of care and medications each waiting day had a significant impact on high treatment costs (OR 1.001). Overall, cost-driving factors resulted in higher median treatment costs of 211,435 €. CONCLUSIONS: Treatment costs in liver transplantation were significantly influenced by identified factors. Long pre-transplant waiting times that increase overall treatment costs need to be alleviated by a substantial increase in donor organs to enable transplantation with lower labMELD-scores. Disease management programs, the implementation of a case management for vulnerable patients, medication plans and patient tracking in a transplant registry may enable cost savings, e.g., by the avoidance of otherwise necessary re-transplants or incorrect medication.
INTRODUCTION: Identification of cost-driving factors in patients undergoing liver transplantation is essential to target reallocation of resources and potential savings. AIM: The aim of this study is to identify main cost-driving factors in liver transplantation from the perspective of the Statutory Health Insurance. METHODS: Variables were analyzed with multivariable logistic regression to determine their influence on high cost cases (fourth quartile) in the outpatient, inpatient and rehabilitative healthcare sectors as well as for medications. RESULTS: Significant cost-driving factors for the inpatient sector of care were a high labMELD-score (OR 1.042), subsequent re-transplantations (OR 7.159) and patient mortality (OR 3.555). Expenditures for rehabilitative care were significantly higher in patients with a lower adjusted Charlson comorbidity index (OR 0.601). The indication of viral cirrhosis and hepatocellular carcinoma resulted in significantly higher costs for medications (OR 21.618 and 7.429). For all sectors of care and medications each waiting day had a significant impact on high treatment costs (OR 1.001). Overall, cost-driving factors resulted in higher median treatment costs of 211,435 €. CONCLUSIONS: Treatment costs in liver transplantation were significantly influenced by identified factors. Long pre-transplant waiting times that increase overall treatment costs need to be alleviated by a substantial increase in donor organs to enable transplantation with lower labMELD-scores. Disease management programs, the implementation of a case management for vulnerable patients, medication plans and patient tracking in a transplant registry may enable cost savings, e.g., by the avoidance of otherwise necessary re-transplants or incorrect medication.
Entities:
Keywords:
Cost analysis of liver transplantation; Cross-sectorial costs; German healthcare costs; High cost cases; Sectors of healthcare
Authors: Christian S van der Hilst; Alexander J C Ijtsma; Maarten J H Slooff; Elisabeth M Tenvergert Journal: Med Care Res Rev Date: 2008-11-03 Impact factor: 3.929
Authors: D A Axelrod; N Dzebisashvili; K Lentine; D L Segev; R Dickson; E Tuttle-Newhall; R Freeman; M Schnitzler Journal: Am J Transplant Date: 2013-10-28 Impact factor: 8.086
Authors: Harald Schrem; Moritz Focken; Bridget Gunson; Benedikt Reichert; Darius Mirza; Hans-Heinrich Kreipe; Desley Neil; Alexander Kaltenborn; Alon Goldis; Christian Krauth; Keith Roberts; Thomas Becker; Jürgen Klempnauer; James Neuberger Journal: Liver Transpl Date: 2016-06 Impact factor: 5.799
Authors: Thomas W Kraus; Markus Mieth; Tobias Schneider; Ingrid Farrenkopf; Arianeb Mehrabi; Peter Schemmer; Jens Encke; Peter Sauer; Markus W Büchler Journal: Transplantation Date: 2005-09-27 Impact factor: 4.939
Authors: Anthony J Perkins; Kurt Kroenke; Jürgen Unützer; Wayne Katon; John W Williams; Carol Hope; Christopher M Callahan Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Donald A Brand; Deborah Viola; Pretam Rampersaud; Patricia A Patrick; William S Rosenthal; David C Wolf Journal: Liver Transpl Date: 2004-08 Impact factor: 5.799
Authors: Paula Buchanan; Nino Dzebisashvili; Krista L Lentine; David A Axelrod; Mark A Schnitzler; Paolo R Salvalaggio Journal: Liver Transpl Date: 2009-10 Impact factor: 5.799
Authors: Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke Journal: J Clin Med Date: 2020-11-05 Impact factor: 4.241